Andere Sprachen Eisai Co., Ltd.

Aktien

855526

JP3160400002

4523

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:34:42 19.04.2024			% 5 Tage	% 1. Jan.
5’901 ^JPY	+1.32%		-2.32%	-16.32%

01.04.	Cogstate ändert Lizenzvereinbarung mit Eisai für Alzheimer-Behandlung	MT
01.04.	BioArctic und Eisai beantragen US FDA-Zulassung für Erhaltungsdosis des Alzheimer-Medikaments	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Eisai: Research on Treatments for Alzheimer's Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category)	18.04.
Eisai's Antiepileptic Drug Fycompa Injection Formulation Launched In Japan	17.04.
It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?	13.04.
French Sales Subsidiary Eisai S.A.S. to Divest Rights for Loxapac And Parkinane LP to CNX Therapeutics	03.04.
Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment	01.04.
BioArctic, Eisai Seek US FDA Approval for Maintenance Dose of Alzheimer’s Disease Drug	01.04.
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	01.04.
Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed	01.04.
Eisai Completes Submission of Leqembi® (Lecanemab-Irmb) Supplemental Biologics License Application for Iv Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDA	01.04.
Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical	29.03.
Eisai's Brain Health Self-Check Tool "NouKNOW" is Certified as "ME-BYO BRAND" by Kanagawa Prefecture	29.03.
Eisai: Discovery Research on Dual Orexin Receptor Antagonist Lemborexant Honored with PSJ Award for Drug Research and Development 2024	29.03.
BioArctic AB - Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	25.03.
BioArctic Flags Delay in EU Health Regulator's Evaluation of Azlheimer’s Disease Drug	22.03.
Lecanemab deliberations at the CHMP regarding the Marketing Authorisation Application in the EU have been rescheduled due to procedural reasons	22.03.
Lifenet to Launch Dementia-Focused Insurance Product in April	22.03.
Lifenet and Eisai Co-Develop Dementia Insurance "be"	21.03.
Eisai Selected as a Nadeshiko Brand 2024 as a Listed Company Excelling in Promotion of Women in the Workplace	21.03.
Professor Lars Lannfelt, awarded Fondation Recherche Alzheimer's European Grand Prix for his contributions to science and treatment of Alzheimer's disease	19.03.
New data on lecanemab presented at the 2024 AD/PD™ congress	11.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Eisai Co., Ltd.

Aktien

855526

JP3160400002

4523

Andere Sprachen

Filter